ListedMainboardKRONOX

Kronox Lab Sciences Limited

Kronox Lab Sciences Limited is a mainboard IPO raising ₹130 Cr at ₹129 – ₹136 a share. It listed on 10 Jun 2024 and trades at ₹151 today, +11.1% against its issue price of ₹136. It was subscribed 118× in total.

136
Issue price
151
Price now
+11.1%
Since issue price
10 Jun 2024
Listed on
118×Subscribed (final) · all exchanges

118.2 times more demand than shares on offer

populated partly populated we hold nothing here — the tab says why

How its cohort has done

92 mainboard issues listed in 2024 that we can price today. This is the group this issue belongs to.

+2.8%
Median return since issue price
47.8%
Now trading below their issue price

Neither figure is a forecast for this issue — they describe what happened to comparable issues. Full cohort analytics →

How the book finished

The category split is the number worth reading, not the total.

QIB89×
Non-institutional303×
Retail56×

Non-institutional: 303× their allocation. Retail: 56×.

See the full split, sub-category by sub-category →

What we hold for this issue

Stated up front on every issue, so a sparse page reads as a fact about the source rather than a broken one.

Category split — who bidQIB, non-institutional and retail, with sub-splits
How demand built over timeNo subscription figure was published
Price-point demand curveLive only — NSE stops serving this once bidding closes
Lead managers and registrar1 bank
Official documents5 documents
Performance since listingComputed from our own daily closes

What happens when

3 Jun 2024Bidding opens
5 Jun 2024Bidding closes
6 Jun 2024Allotment finalised — you find out what you got
7 Jun 2024Money refunded to unsuccessful bidders
10 Jun 2024Shares list and start trading

Track KRONOX LAB SCIENCES LTD

Results, orders, board decisions and every other filing — summarised and sent to your WhatsApp the minute they are out.

Open the company page

Figures are as published by the exchanges and the issuer’s prospectus. MarketPing publishes facts, comparisons and history only — nothing here is a recommendation to apply to this issue, and we do not publish grey market premium.